Prestige Consumer Healthcare Inc
NYSE:PBH
Prestige Consumer Healthcare Inc
NYSE:PBH
Price:
68.53
USD
-1.11%
Market Closed
Market Cap:
$3.2B
Relative Value
The Relative Value of one
PBH
stock under the Base Case scenario is
81.95
USD.
Compared to the current market price of 68.53 USD,
Prestige Consumer Healthcare Inc
is
Undervalued by 16%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PBH
Relative Value
Base Case
81.95
USD
Undervaluation 16%
Multiples Across Competitors
PBH Competitors Multiples
Prestige Consumer Healthcare Inc Competitors
Prestige Consumer Healthcare Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Prestige Consumer Healthcare Inc
NYSE:PBH
|
3.2B USD | 3 | 17.5 | 12.1 | 13.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
951.3B USD | 14.6 | 46.1 | 31.1 | 33.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
595.7B USD | 6.3 | 22.2 | 15.4 | 18.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
282B CHF | 4.6 | 29.9 | 12.7 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
244.9B CHF | 5.6 | 22.4 | 13.8 | 17.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.2B GBP | 5.3 | 30.4 | 16.8 | 23.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
297.5B USD | 4.6 | 16.3 | 10.1 | 12.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.4 | 10.2 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 2.4 | 19.5 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
124.5B USD | 2.6 | 17.6 | 7.4 | 9.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
